Avanos Medical (NYSE:AVNS) Shares Up 0.5% – Time to Buy?

Avanos Medical, Inc. (NYSE:AVNS)’s stock price traded up 0.5% on Tuesday . The stock traded as high as $12.49 and last traded at $12.40. 597,632 shares changed hands during mid-day trading, an increase of 35% from the average session volume of 443,140 shares. The stock had previously closed at $12.34.

Wall Street Analyst Weigh In

AVNS has been the topic of several recent research reports. Wall Street Zen upgraded shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, December 22nd. Finally, Zacks Research downgraded Avanos Medical from a “hold” rating to a “strong sell” rating in a research report on Monday, December 1st. Two research analysts have rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Avanos Medical Price Performance

The company has a current ratio of 2.38, a quick ratio of 1.36 and a debt-to-equity ratio of 0.12. The stock has a 50 day simple moving average of $11.62 and a 200-day simple moving average of $11.60. The firm has a market cap of $575.61 million, a PE ratio of -1.22 and a beta of 1.08.

Avanos Medical (NYSE:AVNS) last issued its earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.10. Avanos Medical had a positive return on equity of 6.21% and a negative net margin of 67.00%.The company had revenue of $177.80 million for the quarter, compared to the consensus estimate of $164.50 million. During the same quarter last year, the company earned $0.33 EPS. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. Equities analysts anticipate that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

Insider Buying and Selling at Avanos Medical

In other news, SVP Kerr Holbrook sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $11.00, for a total transaction of $165,000.00. Following the completion of the transaction, the senior vice president owned 83,860 shares in the company, valued at $922,460. This trade represents a 15.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.64% of the stock is currently owned by insiders.

Institutional Trading of Avanos Medical

A number of large investors have recently made changes to their positions in the business. Versant Capital Management Inc increased its stake in Avanos Medical by 49.7% during the third quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock worth $31,000 after acquiring an additional 894 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Avanos Medical by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after purchasing an additional 1,121 shares during the period. Azzad Asset Management Inc. ADV increased its position in shares of Avanos Medical by 3.0% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 43,230 shares of the company’s stock valued at $500,000 after purchasing an additional 1,240 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Avanos Medical by 6.9% during the 3rd quarter. Federated Hermes Inc. now owns 25,083 shares of the company’s stock valued at $290,000 after purchasing an additional 1,612 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its holdings in Avanos Medical by 8.0% during the 2nd quarter. State of Alaska Department of Revenue now owns 27,504 shares of the company’s stock valued at $336,000 after buying an additional 2,039 shares during the period. 95.17% of the stock is currently owned by institutional investors.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.